Compare · AMGN vs LXEO
AMGN vs LXEO
Side-by-side comparison of Amgen Inc. (AMGN) and Lexeo Therapeutics Inc. (LXEO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMGN and LXEO operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- AMGN is the larger of the two at $186.59B, about 564.4x LXEO ($330.6M).
- Over the past year, AMGN is up 19.1% and LXEO is down 3.4% - AMGN leads by 22.6 points.
- AMGN has been more active in the news (19 items in the past 4 weeks vs 3 for LXEO).
- AMGN has more recent analyst coverage (25 ratings vs 11 for LXEO).
- Company
- Amgen Inc.
- Lexeo Therapeutics Inc.
- Price
- $345.61-1.12%
- $4.23-2.98%
- Market cap
- $186.59B
- $330.6M
- 1M return
- +5.03%
- -27.19%
- 1Y return
- +19.15%
- -3.42%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1983
- 2023
- News (4w)
- 19
- 3
- Recent ratings
- 25
- 11
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Latest AMGN
- AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
- AMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
- AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026
- AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
- Ember LifeSciences announces new strategic investments boosting Series A to $27M
- Director Miles Amy E was granted 665 shares, increasing direct ownership by 13% to 5,640 units (SEC Form 4)
- Director Kullman Ellen Jamison was granted 665 shares, increasing direct ownership by 5% to 14,536 units (SEC Form 4)
- Director Klotman Mary E. was granted 665 shares, increasing direct ownership by 43% to 2,211 units (SEC Form 4)
- Director Jacks Tyler was granted 665 shares, increasing direct ownership by 4% to 18,284 units (SEC Form 4)
- Director Ishrak Omar was granted 665 shares, increasing direct ownership by 10% to 7,359 units (SEC Form 4)
Latest LXEO
- Chief Operating Officer Otero Jose Manuel sold $6,606 worth of shares (1,302 units at $5.07), decreasing direct ownership by 0.99% to 130,088 units (SEC Form 4) (for withholding tax)
- Chief Executive Officer Townsend Richard Nolan sold $16,927 worth of shares (3,342 units at $5.06), decreasing direct ownership by 0.98% to 336,764 units (SEC Form 4) (for withholding tax)
- Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
- Amendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.
- SEC Form 10-Q filed by Lexeo Therapeutics Inc.
- Lexeo Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights
- SEC Form 4 filed by Director Sepp-Lorenzino Laura
- SEC Form 3 filed by new insider Sepp-Lorenzino Laura
- SEC Form DEFA14A filed by Lexeo Therapeutics Inc.